Syros Pharmaceuticals Inc (SYRS)
5.12
+0.04
(+0.79%)
USD |
NASDAQ |
May 07, 16:00
5.16
+0.04
(+0.78%)
After-Hours: 20:00
Syros Pharmaceuticals Enterprise Value: 36.08M for May 6, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 06, 2024 | 36.08M |
| May 03, 2024 | 37.41M |
| May 02, 2024 | 39.26M |
| May 01, 2024 | 45.61M |
| April 30, 2024 | 44.55M |
| April 29, 2024 | 44.02M |
| April 26, 2024 | 35.02M |
| April 25, 2024 | 36.61M |
| April 24, 2024 | 35.82M |
| April 23, 2024 | 37.67M |
| April 22, 2024 | 33.70M |
| April 19, 2024 | 21.80M |
| April 18, 2024 | 26.56M |
| April 17, 2024 | 36.88M |
| April 16, 2024 | 48.78M |
| April 15, 2024 | 43.23M |
| April 12, 2024 | 44.28M |
| April 11, 2024 | 58.30M |
| April 10, 2024 | 47.99M |
| April 09, 2024 | 47.19M |
| April 08, 2024 | 20.74M |
| April 05, 2024 | 25.24M |
| April 04, 2024 | 29.20M |
| April 03, 2024 | 33.44M |
| April 02, 2024 | 24.31M |
| Date | Value |
|---|---|
| April 01, 2024 | 35.02M |
| March 28, 2024 | 43.23M |
| March 27, 2024 | 56.19M |
| March 26, 2024 | 67.03M |
| March 25, 2024 | 71.00M |
| March 22, 2024 | 67.56M |
| March 21, 2024 | 69.41M |
| March 20, 2024 | 69.15M |
| March 19, 2024 | 66.50M |
| March 18, 2024 | 63.07M |
| March 15, 2024 | 60.68M |
| March 14, 2024 | 61.21M |
| March 13, 2024 | 72.85M |
| March 12, 2024 | 72.59M |
| March 11, 2024 | 75.23M |
| March 08, 2024 | 80.79M |
| March 07, 2024 | 85.02M |
| March 06, 2024 | 90.31M |
| March 05, 2024 | 90.81M |
| March 04, 2024 | 102.71M |
| March 01, 2024 | 106.67M |
| February 29, 2024 | 93.71M |
| February 28, 2024 | 91.86M |
| February 27, 2024 | 95.83M |
| February 26, 2024 | 99.80M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-142.68M
Minimum
Dec 20 2022
749.35M
Maximum
Dec 23 2020
135.20M
Average
117.57M
Median
Enterprise Value Benchmarks
| PDS Biotechnology Corp | 103.93M |
| PAVmed Inc | 78.12M |
| Moderna Inc | 38.29B |
| Altimmune Inc | 323.97M |
| iBio Inc | 16.80M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -64.38M |
| Revenue (Quarterly) | 0.386M |
| Total Expenses (Quarterly) | 27.39M |
| EPS Diluted (Quarterly) | -2.22 |
| Profit Margin (Quarterly) | -16.68K% |
| Earnings Yield | -112.4% |
| Normalized Earnings Yield | -86.27 |